AIThe Next Webabout 2 hours ago
Dassault spends $2bn on AI drug-safety firm
1 min read
Dassault Systèmes agreed to buy ArisGlobal for up to $2 billion, paying $1.8 billion in cash plus $200 million tied to AI revenue. ArisGlobal's NavaX system uses generative AI for drug-safety monitoring. The deal targets Dassault's weakest division, where life-sciences revenue fell 4% in Q2 and 12% in Q1.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
